High Purity API Idra-21 Powder For Nootropic Supplyment 22503-72-6 Idra21

Place of Origin CHINA
Brand Name XRD
Certification GMP
Model Number 22503-72-6
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 Kg / Aluminum Foil Bag, 25kg/ Drum, as Require
Delivery Time 1-2days after payment received
Payment Terms T/T, Western Union,Bitcoin
Supply Ability 5000kg/year

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

x
Product Details
Cas No. 22503-72-6 Other Names AMPAKINE
Product NamRopivacainee IDRA 21 Appearance White Powder
Assay 99% IDRA 21 Grade Pharmaceutical Grade
Storage Cool Dried Storage Application Pharmaceutical Raw Intermediates
High Light

raw materials for pharma industry

,

intermediates in pharmaceuticals

Leave a Message
Product Description

High Purity API Idra-21 Powder for Nootropic Supplyment 22503-72-6 Idra21

IDRA-21

Cas Number 22503-72-6

Name: IDRA-21

Formula: C8H9ClN2O2S

Molecular Weight: 232.68726 g/mol

Synonyms: 7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE;7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE 1,1-DIOXIDE;7-CHLORO-3-METHYL-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE S,S-DIOXID

Asssy 99%+

Appearance: White crystalline powder

IIDRA-21 is an ampakine drug derived from aniracetam, IDRA-21 shows nootropic effects in animal studies
While more research is needed for this relatively new compound, it has taken the nootropic community by storm.
This means it is able to improve focus and attention as well as promote learning and memory.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546.Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX-series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.
Studies conducted to evaluate effects of NSI-189 revealed that 40 to 80 mg daily is effective in treating depression and cognitive symptoms amongst healthy patients.
In these trials, there are no serious adverse events recorded. Generally, NSI-189 is well tolerated and safe for human use.

Function
1.Increases in cognitionIncreased Task Accuracy.
2.Increases in Short Term Memory.
3.Potential Therapeutic Effects On Schizophrenia.
4.Potental Therapeutic Effects On Depression.
5.Neuroprotection.
6.Benefits Against Alp-induced Cognitive Deficit.

 

 
 

High Purity API Idra-21 Powder For Nootropic Supplyment 22503-72-6 Idra21 0

 
 

 
Packing:
 
1
 

 

High Purity API Idra-21 Powder for Nootropic Supplyment 22503-72-6 Idra21